Advanced search
Publication Cover
Journal of Blood Medicine Volume 7, 2016 - Issue
Submit an article Journal homepage
58
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A

Jennifer Pocoski1 Bayer HealthCare Pharmaceuticals, Whippany, NJ
,
Nanxin Li2 Analysis Group, Inc., Boston, MACorrespondence[email protected]
,
Rajeev Ayyagari2 Analysis Group, Inc., Boston, MA
,
Nikki Church1 Bayer HealthCare Pharmaceuticals, Whippany, NJ
,
Monika Maas Enriquez1 Bayer HealthCare Pharmaceuticals, Whippany, NJ
,
Quer Xiang2 Analysis Group, Inc., Boston, MA
,
Sneha Kelkar3 Analysis Group, Inc., New York, NY, USA
,
Ella X Du2 Analysis Group, Inc., Boston, MA
,
Eric Q Wu2 Analysis Group, Inc., Boston, MA
&
Jipan Xie3 Analysis Group, Inc., New York, NY, USA
 show all
Pages 129-137 | Published online: 04 Jul 2016

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Maria Elisa Mancuso, Daniel Eriksson, Aletta Falk, Zalmai Hakimi, Piotr Wojciechowski, Marlena Wdowiak & Robert Klamroth. (2023) Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials. Journal of Blood Medicine 14, pages 427-434.
Read now
Teruhisa Fujii, Yuko Kidoguchi, Noriko Takahashi, Eric Yu, Dilinuer Ainiwaer & Aidan Byrne. (2021) Budget impact analysis of Jivi (damoctocog alfa pegol, Bay 94-9027) in severe hemophilia A in Japan. Journal of Medical Economics 24:1, pages 218-225.
Read now
Ana Boban & Cedric Hermans. (2020) An evaluation of the safety and efficacy of turoctocog alfa for hemophilia A. Expert Review of Hematology 13:4, pages 303-311.
Read now
Katharine Batt, Wei Gao, Rajeev Ayyagari, Céline Deschaseaux, Parth B Vashi, Zhiwen Yao, Yao Wang, Sophia Kessabi & Robert Klamroth. (2019) Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A. Journal of Blood Medicine 10, pages 147-159.
Read now

Articles from other publishers (4)

Carsten Bokemeyer, Noman Paracha, Ulrik Lassen, Antoine Italiano, Sean D. Sullivan, Marisca Marian, Nicoletta Brega & Jesus Garcia-Foncillas. (2023) Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data. JCO Precision Oncology:7.
Crossref
Santiago Bonanad, Ramiro Núñez, Jose Luis Poveda, Karin Kurnik, Georg Goldmann, Valeska Andreozzi, Björn Vandewalle & Sandra Santos. (2021) Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A. Advances in Therapy 38:9, pages 4872-4884.
Crossref
Arnaud Bourdin, Don Husereau, Nicolas Molinari, Sarowar Golam, Mohd Kashif Siddiqui, Leandro Lindner & Xiao Xu. (2020) Matching‐adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics. Clinical & Experimental Allergy 50:4, pages 442-452.
Crossref
Arnaud Bourdin, Don Husereau, Nicolas Molinari, Sarowar Golam, Mohd Kashif Siddiqui, Leandro Lindner & Xiao Xu. (2018) Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review . European Respiratory Journal 52:5, pages 1801393.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.